Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Director departure
Cyteir Therapeutics, Inc. (CYT) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/23/2023 8-K Quarterly results
Docs: "Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights - Initial data from Phase 1 combination with capecitabine in advanced ovarian cancer are expected in mid-2023 - Dose for the Phase 1 combination trials identified as 400mg daily - Ended 2022 with approximately $147 million in cash; Projected cash runway into 2026"
11/07/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
Docs: "INVESTOR CONTACT:"
05/05/2022 8-K Quarterly results
03/16/2022 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: "CYTEIR THERAPEUTICS, INC CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Operating expenses: Research and development $ 8,205 $ 4,214 $ 22,704 $ 12,848 General and administrative 3,547 831 7,693 2,715 Total operating expenses 11,752 5,045 30,397 15,563 Loss from operations Other income : Other income 48 9 86 100 Total other income 48 9 86 100 Net loss $ $ $ $ Net loss per share—basic and diluted $ $ $ $ Weighted-average common stock outstanding—basic and diluted 35,062,900 1,463,084 14,229,834 1,428,311 CYTEIR THERAPEUTICS, INC CONDENSED BALANCE SHEETS September 30, 2021 Assets Current assets: Cash and cash equivalents $ 199,822 $ 10,938 Prepaid expenses and other current assets 4,397 1,193 Tot..."
08/09/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy